DOL.TO 1.05CRCL 0CLS.TO 49.22ZGI.TO -0.74XMW.TO 0.11XMU.TO 0.21MSFT 23.25
Novavax Inc (NVAX)

NASDAQ:NVAX

Novavax Inc (NVAX)

10.97
+0.65 (6.30%)
as of May 29, 2026, 8:00:00 pm Market Open.
33 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
DON'T BUY

Novavax Inc(NVAX)

Jun 14, 2024

Since Covid, this has lost too much money for investors.

Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$14.40

Stock price when the opinion was issued

$10.97

As of May 29, 2026. Market Open.

Pharma & Healthcare
SELL

Novavax Inc(NVAX)

May 11, 2022
Historically not a successful vaccine developer. Shares were $258 last November but fallen to $42. This can fall further. He's never liked it.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad Money
No
Unlock Rating
$42.90

Stock price when the opinion was issued

$10.97

As of May 29, 2026. Market Open.

Pharma & Healthcare
DON'T BUY

Novavax Inc(NVAX)

Feb 07, 2022
The variability around earnings makes it interesting to trade, but he would not recommend investing in it. Very volatile. No insight for approval. Prefers using XPI ETF to trade the sector. NVAX is not a name he owns.
Photo of Larry Berman CFA, CMT, CTALarry Berman CFA, CMT, CTA
No
Unlock Rating
$94.81

Stock price when the opinion was issued

$10.97

As of May 29, 2026. Market Open.

Pharma & Healthcare
DON'T BUY

Novavax Inc(NVAX)

Jan 26, 2022
The share price and PE have plunged in the past year. Though cheaper to buy, he passes, because they haven't gotten FDA approval for their Covid vaccine.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad Money
No
Unlock Rating
$79.06

Stock price when the opinion was issued

$10.97

As of May 29, 2026. Market Open.

Pharma & Healthcare
DON'T BUY

Novavax Inc(NVAX)

Dec 20, 2021
Issued a Covid vaccines that the EU and WHO approved recently. He likes Pfizer in this group; you don't need another one. NVAX is up 6% in the past week.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad Money
No
Unlock Rating
$202.00

Stock price when the opinion was issued

$10.97

As of May 29, 2026. Market Open.

Pharma & Healthcare
WEAK BUY

Novavax Inc(NVAX)

Dec 07, 2021
Eventually, a full, broad-spectrum vaccine will be in place to cover Covid. Will MRNA technology also develop drugs to tackle TV and HIV and other diseases. Novartis offers more a strong balance sheet and a just-announced $20 billion inflow, based on tuck-in acquisition. NVAX is fine, but there are better companies.
Photo of Darren SissonsDarren SissonsUnlock Rating
$178.29

Stock price when the opinion was issued

$10.97

As of May 29, 2026. Market Open.

Pharma & Healthcare
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Novavax Inc(NVAX)

Oct 05, 2021
(A Top Pick Jul 21/21, Down 16.7%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with NVAX has triggered its stop at $175. To remain disciplined, we recommend covering the position at this time. Combined with the previous recommendation to cover half the position, this results in a net investment gain of 6%.
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$170.00

Stock price when the opinion was issued

$10.97

As of May 29, 2026. Market Open.

Pharma & Healthcare
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Novavax Inc(NVAX)

Sep 09, 2021
(A Top Pick Jul 22/21, Up 29.4%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with NVAX has achieved its target at $272. To be disciplined, we recommend covering half the position at this time and trailing up the stop (from $160) to $175.
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$258.85

Stock price when the opinion was issued

$10.97

As of May 29, 2026. Market Open.

Pharma & Healthcare
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Novavax Inc(NVAX)

Jul 22, 2021
Stockchase Research Editor: Michael O'Reilly NVAX is applying for Emergency Use Authorization for its COVID-19 vaccine as experts believe annual boosters may be required as with the annual flu shots. It has achieved over 89% efficacy and does not require deep freeze storage -- a huge advantage. It has agreements already in place for 180 million doses in the UK, Canada, and Australia when approved. We would buy this with a stop loss at $160, looking to achieve $272 -- upside potential over 27%. Yield 0%. (Analysts’ price target is $271.75)
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$210.18

Stock price when the opinion was issued

$10.97

As of May 29, 2026. Market Open.

Pharma & Healthcare
DON'T BUY

Novavax Inc(NVAX)

Jun 15, 2021
Recently announced an effective Covid vaccine In 2019, they had less than $50 million in revenue. It was nascent and now prominent. They could participate in the booster Covid market, and they need to live up to their current market cap of $14 billion. NVAX has to vaccinate a quarter of the world's population to trade at 1x revenues. There's a lot of hope built into the shares that they succeed. He can't buy this and sleep at night.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
N/A

Stock price when the opinion was issued

$10.97

As of May 29, 2026. Market Open.

Pharma & Healthcare
DON'T BUY

Novavax Inc(NVAX)

May 07, 2021

It's not worth what it's selling for, and the stock should be lower. Moderna, in contrast, has more drugs in the pipeline, and he prefers this stock.

Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$176.05

Stock price when the opinion was issued

$10.97

As of May 29, 2026. Market Open.

Pharma & Healthcare
DON'T BUY

Novavax Inc(NVAX)

Mar 18, 2021

NVAX vs. PFE He'd absolutely go with PFE. Investors have been chasing growthy parts of the market and ignoring the stable areas. Vaccines don't move the needle for PFE the way they do for the others, but a great long-term investment if you think rates will stay lower. PFE is mature, decent balance sheet, good valuation.

Photo of John ZechnerJohn ZechnerUnlock Rating
$219.54

Stock price when the opinion was issued

$10.97

As of May 29, 2026. Market Open.

Pharma & Healthcare
DON'T BUY

Novavax Inc(NVAX)

Jul 24, 2020
There is almost an arms race that is going on with respect to vaccine development. We need to wait to see how human testing is going to work out. There will be lots of volatility in the meantime. He is not interested in playing a specific name -- much like what happened with marijuana stocks. He would look to companies that will provide syringes instead.
Photo of Brett Girard, CPA, CA, CFABrett Girard, CPA, CA, CFA
No
Unlock Rating
$133.61

Stock price when the opinion was issued

$10.97

As of May 29, 2026. Market Open.

Pharma & Healthcare
Showing 1 to 13 of 13 entries
  • «
  • ‹
  • 1
  • ›
  • »

Novavax Inc (NVAX) Frequently Asked Questions

What is Novavax Inc stock symbol?

Novavax Inc is a American stock, trading under the symbol NVAX (previously NVAX-Q on Stockchase) on the NASDAQ (NVAX). It is usually referred to as NASDAQ:NVAX or NVAX

Is Novavax Inc a buy or a sell?

In the last year, there was no coverage of Novavax Inc published on Stockchase.

Is Novavax Inc a good investment or a top pick?

Novavax Inc was recommended as a Top Pick by Brett Girard, CPA, CA, CFA on 2020-07-24. Read the latest stock experts ratings for Novavax Inc.

Why is Novavax Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for help on deciding if you should buy, sell or hold the stock.

Is Novavax Inc worth watching?

0 stock analysts on Stockchase covered Novavax Inc in the last year. It is a trending stock that is worth watching.

What is Novavax Inc stock price?

On 2026-05-29, Novavax Inc (NVAX) stock closed at a price of $10.97.

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

DELL 103.86$420.91
MSFT 23.25$450.24
AWK 0.92$123.27
DELL 103.86$420.91
IGV 5.98$101.66

Today's Top Picks

DOL.TO 1.05$176.3
CRCL 0$
CLS.TO 49.22$533.01
ZGI.TO -0.74$57.31
XMW.TO 0.11$59.3

Popular Articles

Latest Sell Signals

COST -38.88$956.32
CAT -11.8$875.87
T.TO 0.03$17.31
BB.TO 0.25$12.36
GEV -27.68$968.32

Most Recent Experts

Kevin Simpson

Kevin Simpson

Capital Wealth Planning

Karen Firestone, CEO, Aureus Asset Management

Karen Firestone, CEO, Aureus Asset Management

Aureus Asset Management

Bryn Talkington

Bryn Talkington

Requisite Capital Management

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Brianne Gardner

Brianne Gardner

Raymond James

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica